Fifth Third Bancorp’s BioCryst Pharmaceuticals BCRX Stock Holding History

Fifth Third Bancorp’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Buy	119,942 +119,458	+24,681%	+$1.08M	﹤0.01%	1589
2026 Q1	$4.61K	Buy	+484	New	+$3.76K	﹤0.01%	3888
2024 Q1	–	Sell	-3,500	Closed	-$21K	–	2375
2023 Q4	$21K	Sell	3,500 -20	-0.6%	-$116	﹤0.01%	1753
2023 Q3	$24.9K	Buy	3,520 +3,500	+17,500%	+$25.1K	﹤0.01%	1650
2023 Q2	$141	Buy	+20	New	+$160	﹤0.01%	2589

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Fifth Third Bancorp's BCRX Position: Q2 2026 in Review

Fifth Third Bancorp increased its BioCryst Pharmaceuticals (BCRX) stake by 24,681% in Q2 2026, buying an estimated $1.08M and bringing the position to 119,942 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1589.

Fifth Third Bancorp first reported a position in BCRX in Q2 2023 and has held it in 5 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Fifth Third Bancorp held 119,942 shares of BioCryst Pharmaceuticals worth $1.2M as of Q2 2026.
Fifth Third Bancorp bought 119,458 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
BioCryst Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1589 holding.
Fifth Third Bancorp first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.